alone or in combination with other constructs, may be used in a vaccine composition against all four dengue virus serotypes.In certain embodiments, compositions may include compounds of more than one dengue virus serotype, such as dengue-1 virus (den-1), dengue-2 virus (den-2), dengue-3 ...
E. et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect. Dis. 14, 830–838 (2014). Article CAS PubMed PubMed Central Google Scholar...
A dengue vaccine must be able to elicit high efficacy against the four viruses, be safe and be able to, ultimately, help contain the virus spread. In other words, it must induce protection against at least three and preferably to all four dengue viruses at the same time, as if it were ...
Vaccines for dengue are in various stages of development; in Brazil, only one commercial formulation is available (CYD-TDV), which was developed by Sanofi Pasteur. Methods: To evaluate the efficacy of Dengue vaccine, a systematic review with a meta-analysis was conducted using randomized ...
Hence, a single 100 ml Vero cell culture can yield nearly 1 million doses of vaccine for a single DENV serotype. It remains to be demonstrated that a non-living vaccine can be made that is as immunogenic and as economically feasible as a live attenuated virus. However, if this can be ...
several challenges impede the development of effective DENV vaccines, such as the lack of suitable animal models and the antibody-dependent enhancement phenomenon. Although no licensed DENV vaccine is available, significant progress has been made. This review summarizes candidate DENV vaccines from recent...
incidence in humans revealed significant reductions in symptomatic dengue and hospitalizations for dengue in areas wherewMel mosquitoes had been introduced versus areas with normalA. aegyptipopulations. In 2019 the U.S.Food and Drug Administrationapproved the firstvaccine to prevent dengue in individuals ...
Notwithstanding, a WNV vaccine for equine use has been approved. It is based on immunization with formalin-inactivated WNV, a recombinant canarypox virus vector, and a DNA plasmid expressing WNV prM and E proteins [31]. Considering all of this, developing effective therapeutic approaches remains ...
A vaccine called Dengvaxia can help prevent dengue in children aged 6 to 16 who have tested positive for the virus before and who live in areas where dengue spreads. The vaccine is about 80% effective, but children need three doses to get full protection against the virus. ...
Formulation of the viruses of the invention can be carried out using methods that are standard in the art. Numerous pharmaceutically acceptable solutions for use in vaccine preparation are well known and can readily be adapted for use in the present invention by those of skill in this art (see...